文献速递妇科

子宫内膜癌TCGA分子分组的预后:汇总数据

TCGA molecular groups of endometrial cancer: Pooled data about prognosis.
PubMed 文献 · Gynecol Oncol · 2019-08-29

该研究通过系统综述与Meta分析汇总6项研究共2818例子宫内膜癌患者,以p53wt为参照,评估TCGA四个分子分组的预后。结果显示p53mt组总生存、疾病特异性生存和无进展生存的风险比最高,POLEmt组最低,MSI组与p53wt组有重叠但受不良临床病理因素影响而恶化。

要点

  • p53mt组预后最差,总生存风险比为3.179(单变量)和1.986(多变量)。
  • POLEmt组预后最好,总生存风险比为0.589(单变量)和0.795(多变量)。
  • MSI组预后与p53wt组重叠,但不良临床病理因素可使其恶化。

核心结论

  • p53mt组预后始终最差,且不良临床病理因素进一步使其恶化。
  • MSI组预后与p53wt组有重叠,但不良临床病理因素使其恶化。
  • POLEmt组预后最好,似乎不受临床病理因素显著影响。

研究设计与样本

  • 系统综述与Meta分析,检索7个电子数据库从建库至2019年4月,纳入6项研究共2818例患者。

主要发现

  • 总生存:p53mt组汇总HR为3.179(单变量)和1.986(多变量),MSI组为1.522和1.192,POLEmt组为0.589和0.795,均以p53wt为参照。
  • 疾病特异性生存:p53mt组汇总HR为5.052(单变量)和2.133(多变量),MSI组为1.965和1.068,POLEmt组为0.552和0.325。
  • 无进展生存:p53mt组汇总HR为3.512(单变量)和1.833(多变量),MSI组为1.354和0.817,POLEmt组为0.287和0.217。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: After The Cancer Genome Atlas (TCGA) findings, four novel prognostic groups may direct the management of endometrial cancer (EC): POLE-mutated/ultramutated (POLEmt), microsatellite-instable/hypermutated (MSI), copy-number-low/p53-wild-type (p53wt), and copy-number-high/p53-mutated (p53mt). However, data about prognosis in each group are different across the studies, and definitive pooled estimates are lacking after validation series. Such data may be crucial in directing clinical study design and establishing the optimal tailored management of patients. AIM: To provide pooled estimates of hazard ratio (HR) for overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS) in each prognostic group. MATERIALS AND METHODS: A systematic review and meta-analysis was performed by searching 7 electronic databases, from their inception to April 2019, for studies assessing prognosis in each TCGA EC group. Both univariable and multivariable HR analysis was performed for OS, DSS and PFS in each group, using p53wt as reference group. RESULTS: Six studies with 2818 patients were included. Regarding OS, pooled HRs were 3.179 and 1.986 for p53mt group, 1.522 and 1.192 for MSI group, and 0.589 and 0.795 for POLEmt group at univariable and multivariable analyses, respectively. Regarding DSS, pooled HR were 5.052 and 2.133 for p53mt group, 1.965 and 1.068 for MSI group, and 0.552 and 0.325 for POLEmt group at univariable and multivariable analyses, respectively. Regarding PFS, pooled HR were 3.512 and 1.833 for p53mt group, 1.354 and 0.817 for MSI group, and 0.287 and 0.217 for POLEmt group at univariable and multivariable analyses, respectively. CONCLUSIONS: Prognosis of p53mt group is consistently the worst one and is further worsened by unfavorable clinicopathological factors. Prognosis of MSI group overlaps with p53wt group but is worsened by unfavorable clinicopathological factors. Prognosis of POLEmt group is the best one and does not seem to be significantly affected by clinicopathological factors.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Raffone A, Travaglino A, Mascolo M, et al. TCGA molecular groups of endometrial cancer: Pooled data about prognosis. Gynecol Oncol. 2019. PMID: 31472940. doi:10.1016/j.ygyno.2019.08.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。